Eli Lilly Completes $9.0 Billion Debt Offering, Funds Centessa Acquisition
LLY sits 63% above its 52-week low of $623.78.
Summary
Eli Lilly completed a $9.0 billion debt offering, raising approximately $8.94 billion in net proceeds, with a significant portion explicitly tied to financing the previously announced Centessa acquisition.
Key Events · Financing and Capital Events · LLY
-
Completed $9.0 Billion Debt Offering
Eli Lilly completed an offering of various Floating Rate Notes and Fixed Rate Notes totaling $9.0 billion in aggregate principal amount.
-
Raised $8.94 Billion in Net Proceeds
The company received approximately $8.94 billion in net proceeds from the debt offering, after deducting underwriting discounts.
-
Financing Linked to Centessa Acquisition
A significant portion of the notes ($6.25 billion) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by March 31, 2027, explicitly linking the financing to the previously announced $6.3 billion acquisition.
-
Diverse Note Maturities and Rates
The offering includes both floating and fixed-rate notes with maturities ranging from 2028 to 2066, diversifying the company's debt profile.
Analysis · LLY · Life Sciences
Eli Lilly has successfully completed a substantial debt offering, raising approximately $8.94 billion in net proceeds. This capital raise is significant for funding the company's strategic growth initiatives. A key detail is the special mandatory redemption clause for $6.25 billion of the notes, explicitly linking this financing to the previously announced Centessa acquisition. This demonstrates the company's commitment to its M&A strategy and provides the necessary capital to execute it, following a period of strong operational performance and product development.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LLY was trading at $1,016.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $959.5B. The 52-week trading range was $623.78 to $1,133.95. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.